Search

Your search keyword '"Barrón F"' showing total 2 results
Start Over Author "Barrón F" Journal esmo open
2 results on '"Barrón F"'

1. Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors

Author

Rojas, L., Mayorga, D., Ruiz-Patiño, A., Rodríguez, J., Cardona, A.F., Archila, P., Avila, J., Bravo, M., Ricaurte, L., Sotelo, C., Arrieta, O., Zatarain-Barrón, Z.L., Carranza, H., Otero, J., Vargas, C., Barrón, F., Corrales, L., Martín, C., Recondo, G., Pino, L.E., Bermudez, M.A., Gamez, T., Ordoñez-Reyes, C., García-Robledo, J.E., de Lima, V.C., Freitas, H., Santoyo, N., Malapelle, U., Russo, A., Rolfo, C., and Rosell, R.

Published
2022
Full Text
View/download PDF

2. Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors

Author

L. Rojas, D. Mayorga, A. Ruiz-Patiño, J. Rodríguez, A.F. Cardona, P. Archila, J. Avila, M. Bravo, L. Ricaurte, C. Sotelo, O. Arrieta, Z.L. Zatarain-Barrón, H. Carranza, J. Otero, C. Vargas, F. Barrón, L. Corrales, C. Martín, G. Recondo, L.E. Pino, M.A. Bermudez, T. Gamez, C. Ordoñez-Reyes, J.E. García-Robledo, V.C. de Lima, H. Freitas, N. Santoyo, U. Malapelle, A. Russo, C. Rolfo, R. Rosell, Rojas, L, Mayorga, D, Ruiz-Patiño, A, Rodríguez, J, Cardona, A F, Archila, P, Avila, J, Bravo, M, Ricaurte, L, Sotelo, C, Arrieta, O, Zatarain-Barrón, Z L, Carranza, H, Otero, J, Vargas, C, Barrón, F, Corrales, L, Martín, C, Recondo, G, Pino, L E, Bermudez, M A, Gamez, T, Ordoñez-Reyes, C, García-Robledo, J E, de Lima, V C, Freitas, H, Santoyo, N, Malapelle, U, Russo, A, Rolfo, C, and Rosell, R

Subjects
Vascular Endothelial Growth Factor A, Cancer Research, Lung Neoplasms, Papillomavirus Infections, Adenocarcinoma of Lung, Fibrosis, lung cancer, Oncology, HPV infection, Humans, immunotherapy, RNA, Messenger, Immune Checkpoint Inhibitors, Retrospective Studies
Abstract

Human papilloma virus (HPV) has been associated with the development and modulation of response in a series of neoplasms. In the case of lung adenocarcinoma, its role in etiology and pathogenesis is still controversial. Considering that this infection brings foreign epitopes, it could be of prognostic significance in patients with lung adenocarcinoma treated with immunotherapy.In a retrospective cohort study we evaluated the presence of HPV genomic material in lung adenocarcinoma primary lesions with the INNO-LiPA platform. Viral replication was also evaluated by detecting the presence of oncoprotein E6/E7 messenger RNA (mRNA) by quantitative RT-PCR. To confirm possible hypotheses regarding viral oncogenesis, vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1 (HIF1) were evaluated with stromal fibrosis and immunoscore.A total of 133 patients were included in the analysis, of whom 34 tested positive for HPV, reaching an estimated prevalence of 25.6% [95% confidence interval (CI) 18.2% to 32.9%]. E6/7 mRNA was identified in 28 out of the 34 previously positive cases (82.3%). In immune checkpoint inhibitor (ICI)-treated patients, the median overall survival reached 22.3 months [95% CI 19.4 months- not reached (NR)] for HPV-negative and was not reached in HPV-positive (HPV+) ones (95% CI 27.7-NR; P = 0.008). With regard to progression-free survival, HPV- patients reached a median of 9.2 months (95% CI 7.9-11.2 months) compared to 14.3 months (95% CI 13.8-16.4 months) when HPV was positive (P = 0.001). The overall response rate for HPV+ patients yielded 82.4% compared to 47.1% in negative ones. No differences regarding programmed death-ligand 1, VEGF, HIF1, stromal fibrosis, or immunoscore were identified.In patients with HPV+ lung adenocarcinoma, a significant benefit in overall response and survival outcomes is observed.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results